CTV London reports Eli Lilly's experimental drug outperformed Ozempic on both weight loss and blood sugar control in a head-to-head study.
Recap by typeshit. Post by CTV London on X.
A physio fielding years of peptide questions says strong studies are lacking, while noting that a lack of evidence doesn't prove they fail.
Up to half of participants in the two trials of the experimental drug ended up with only mild sleep apnea, per the post.
Nippard puts the two approved drugs on top for supervised weight loss and holds retatrutide at B-tier until it is approved.
Bloomberg traces how Amgen used genetic data from Iceland to guide its obesity drug research.
Earnings came to $7.22 a share, up from $6.21 a year earlier, with weight loss drugs leading the gains, per The Wall Street Journal.
Hims & Hers and a peptide academy met White House reviewers before release, and the Partnership for Safe Medicines has petitioned the FDA to block it.
Loading…